Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
August 14 2017 - 10:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SEC File Number
000-51474
|
|
CUSIP Number
74365B109
|
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
¨
Form 10-K
¨
Form 20-F
¨
Form 11-K
x
Form 10-Q
¨
Form 10-D
¨
Form N-SAR
¨
Form N-CSR
For period ended:
June 30,
2017
|
¨
|
Transition Report on Form 10-K
|
|
¨
|
Transition Report on Form 20-F
|
|
¨
|
Transition Report on Form 11-K
|
|
¨
|
Transition Report on Form 10-Q
|
|
¨
|
Transition Report on Form N-SAR
|
For the transition period ended: _________________________
Read Instruction (on back page) Before
Preparing Form. Please Print or Type.
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:
PART I—REGISTRANT INFORMATION
Protea Biosciences Group,
Inc.
Full Name of Registrant
1311 Pineview Drive, Suite 501
Address of Principal Executive Office
(Street and Number)
Morgantown, WV 26505
City, State and Zip Code
PART II—RULE 12b-25(b) and (c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate)
x
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
x
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
¨
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III—NARRATIVE
State below in reasonable detail the reason
why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed
time period.
(Attach extra sheets if needed)
The Registrant is unable to file its
Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2017 (the “Report”) by the prescribed date of August
14, 2017 without unreasonable effort or expense because the Registrant and its independent auditor need additional time to complete
certain disclosures and analyses required to be included in the Report. In accordance with Rule 12b-25 promulgated under
the Securities Exchange Act of 1934, as amended, the Registrant intends to file its Report on or prior to the fifth calendar day
following the prescribed due date.
PART IV—OTHER INFORMATION
|
(1)
|
Name and telephone number
of person to contact with regard to this notification.
|
|
Stephen Turner
|
|
(304)
|
|
292-2226
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic
reports required under Section 13 or 15(d) or the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been
filed? If the answer is no, identify report(s).
|
x
Yes
¨
No
|
(3)
|
Is it anticipated that
any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
|
x
Yes
¨
No
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reason why a reasonable estimate of the results cannot
be made.
It is likely that there will be significant
changes in the Company's revenues and operating expenses for the three months ended June 30, 2017 as compared to the three months
ended June 30, 2016 and for the six months ended June 30, 2017 as comparted to the six months ended June 30, 2016. However, a reasonable
estimate of such changes cannot be made at this time because the financial statements are still being compiled.
Protea Biosciences Group, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed
on its behalf by the undersigned heretofore duly authorized.
Date: August 14, 2017
|
By
|
/s/ Stephen Turner
|
|
Name: Stephen Turner
|
|
Title: Chief Executive Officer
|